Winning Points Advisors LLC Purchases New Position in ImmunityBio, Inc. $IBRX

Winning Points Advisors LLC purchased a new stake in ImmunityBio, Inc. (NASDAQ:IBRX) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 722,373 shares of the company’s stock, valued at approximately $1,430,000. ImmunityBio comprises about 1.3% of Winning Points Advisors LLC’s portfolio, making the stock its 14th largest holding. Winning Points Advisors LLC owned 0.07% of ImmunityBio at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Diversify Advisory Services LLC bought a new stake in ImmunityBio in the second quarter worth about $27,000. Truist Financial Corp bought a new stake in ImmunityBio in the third quarter worth about $27,000. Swiss Life Asset Management Ltd bought a new stake in ImmunityBio in the third quarter worth about $27,000. Wealthfront Advisers LLC bought a new stake in ImmunityBio in the third quarter worth about $28,000. Finally, Sei Investments Co. bought a new stake in ImmunityBio in the second quarter worth about $31,000. Institutional investors own 8.58% of the company’s stock.

Analyst Upgrades and Downgrades

IBRX has been the subject of several analyst reports. The Goldman Sachs Group reissued a “buy” rating on shares of ImmunityBio in a research note on Monday, February 23rd. Piper Sandler reissued an “overweight” rating and issued a $12.00 price objective (up from $7.00) on shares of ImmunityBio in a research note on Wednesday, March 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of ImmunityBio in a research note on Tuesday, April 14th. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of ImmunityBio in a research note on Tuesday, June 2nd. Finally, BTIG Research reissued a “buy” rating and issued a $12.00 price objective on shares of ImmunityBio in a research note on Thursday, May 21st. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, ImmunityBio has an average rating of “Moderate Buy” and an average price target of $14.20.

ImmunityBio Stock Performance

ImmunityBio stock opened at $7.20 on Friday. The company has a 50 day moving average price of $7.55 and a 200-day moving average price of $6.12. ImmunityBio, Inc. has a fifty-two week low of $1.95 and a fifty-two week high of $12.43. The company has a market capitalization of $7.54 billion, a PE ratio of -8.47 and a beta of 0.03.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.54). The firm had revenue of $44.21 million for the quarter, compared to analysts’ expectations of $43.07 million. On average, analysts forecast that ImmunityBio, Inc. will post -0.31 earnings per share for the current year.

Insider Transactions at ImmunityBio

In other ImmunityBio news, Director Barry J. Simon sold 23,033 shares of ImmunityBio stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $7.18, for a total value of $165,376.94. Following the transaction, the director directly owned 2,827,788 shares of the company’s stock, valued at approximately $20,303,517.84. The trade was a 0.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 69.48% of the company’s stock.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.